Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Eva P. Galiza
Observed names:
E Galiza,
E P Galiza,
E. P. Galiza,
Eva Galiza,
Eva P Galiza,
Galiza, Eva
show all 6
Institution:
City St George's, University of London
Observed institutions:
University of London,
National Health Service,
St George's Hospital,
University of Leicester,
St George's, University of London,
St George’s University Hospitals NHS Foundation Trust,
St George's Hospital,
City St George's, University of London
show all 8
ORCID:
0000-0002-2653-6079
Observed ORCID:
0000-0002-2653-6079
OpenAlex ID:
A5015357500
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
2020
·
Merryn Voysey
, Sue Ann Costa Clemens
, et al.
·
The Lancet
·
5,086
PDF
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
2020
·
Pedro M Folegatti
, Katie J Ewer
, et al.
·
The Lancet
·
2,584
PDF
Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
2021
·
Merryn Voysey
, Sue Ann Costa Clemens
, et al.
·
The Lancet
·
1,199
PDF
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
2021
·
Katherine R. W. Emary
, Tanya Golubchik
, et al.
·
The Lancet
·
676
PDF
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
2021
·
Xinxue Liu
, Robert H Shaw
, et al.
·
The Lancet
·
508
PDF
Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin
2009
·
David J. M. Lewis
, Zhiming Huo
, et al.
·
PLoS ONE
·
331
PDF
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
2021
·
Amy Flaxman
, Natalie G Marchevsky
, et al.
·
The Lancet
·
267
PDF
Incidence, Etiology, and Outcome of Bacterial Meningitis in Infants Aged <90 Days in the United Kingdom and Republic of Ireland: Prospective, Enhanced, National Population-Based Surveillance
2014
·
I. O. Okike
, A. P. Johnson
, et al.
·
Clinical Infectious Diseases
·
216
Maternal vaccination: a review of current evidence and recommendations
2021
·
Melanie Etti
, Anna Calvert
, et al.
·
American Journal of Obstetrics and Gynecology
·
182
PDF
Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age: A Double-blind Randomized Active-controlled Trial
2010
·
Matthew D. Snape
, Chaam L. Klinger
, et al.
·
The Pediatric Infectious Disease Journal
·
135
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial
2022
·
Paul T Heath
, Eva P Galiza
, et al.
·
Clinical Infectious Diseases
·
73
PDF
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial
2023
·
Ivan T Lee
, Catherine A Cosgrove
, et al.
·
The Lancet Infectious Diseases
·
57
PDF
COVAC1 Phase 2a Expanded Safety and Immunogenicity Study of a Self-Amplifying RNA Vaccine Against SARS-CoV-2
2022
·
Alex J. Szubert
, Katrina M. Pollock
, et al.
·
EClinicalMedicine
·
47
Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis
2022
·
Natalina Sutton
, Alberto San Francisco Ramos
, et al.
·
Expert Review of Vaccines
·
46
PDF
Safety and Immunogenicity of the ChadOx1 nCoV-19 (AZD1222) Vaccine in Children Aged 12-17 Years: A Preliminary Report of a Phase 2, Single-Blind, Randomised Controlled Trial (COV006)
2021
·
Grace Li
, Federica Cappuccini
, et al.
·
The Lancet
·
44
PDF
Improving the outcome of neonatal meningitis
2009
·
Eva P Galiza
, Paul T Heath
·
Current Opinion in Infectious Diseases
·
36
Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis
2024
·
Alberto San Francisco Ramos
, Carolina Liu Sanchez
, et al.
·
Expert Review of Vaccines
·
24
PDF
Viral bronchiolitis management in hospitals in the UK
2018
·
Elliott J. Carande
, Eva P. Galiza
, et al.
·
Journal of Clinical Virology
·
19
PDF
Immunogenicity and safety of a group B Streptococcus vaccine (GBS-AlpN) in pregnant women and their infants: a phase 2, multicentre, observer-blind, randomised, placebo-controlled study
2025
·
Paul T Heath
, Ntokozo Zuma-Gwala
, et al.
·
The Lancet Infectious Diseases
·
13
Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019–2021
2022
·
Helen Ratcliffe
, K S Tiley
, et al.
·
Archives of Disease in Childhood
·
11
PDF
Immunogenicity of booster doses of 13-valent pneumococcal conjugate and Hib/MenC vaccines given at 12 months of age in the UK
2009
·
J.Y. Hughes
, Snape
, et al.
·
ePrints Soton (University of Southampton)
·
10
Pneumococcal conjugate vaccines. A review.
2007
·
E P Galiza
, P T Heath
·
PubMed
·
10
COVID-19 vaccines in pregnancy
2021
·
Eva Galiza
, Paul Heath
·
http://isrctn.com/
·
9
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents
2023
·
Helen Ratcliffe
, Karen S. Tiley
, et al.
·
iScience
·
8
PDF
Pertussis
2021
·
Eva P Galiza
, Anna Calvert
, et al.
·
Medicine
·
8
Show more works
View as search
Works count:
56
Citation count:
11,730
H-index:
19
I10-index:
25
Year
Topic
Type